Clinical trialPhase 1 / Phase 2Completed
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A Cancer-Specific Plectin (CSP)-Targeting Functional Antibody in Solid Tumors That Are Likely to Express CSP
- Outcome
- Finished, no results posted
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 14 January 2022
- Ended
- 30 September 2023
- Enrollment
- 35 participants
- Sites
- 9
- Primary outcomes
- Maximum plasma concentration (Cmax)
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 29 January 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study is a first-in-human, Phase 1, open label, multicenter, dose escalation study with expansion at the RP2D, to evaluate the safety, tolerability, and preliminary efficacy of ZB131 in patients with solid tumors where prevalence of CSP expression is high. Approximately 12 to 24 patients will be enrolled in the Dose Escalation Stage; the total number of patients will depend on the dose level at which the RP2D is defined. Patients who meet the eligibility criteria during Screening will enter the treatment period. ZB131 will be given via IV every week. Patients will be treated until disease progression or unacceptable toxicities occur.
Detailed description public domain (ClinicalTrials.gov)
This study is a first-in-human, Phase 1, open label, multicenter, dose escalation study with expansion at the RP2D, to evaluate the safety, tolerability, and preliminary efficacy of ZB131 in patients with solid tumors where prevalence of CSP expression is high. Approximately 12 to 24 patients will be enrolled in the Dose Escalation Stage; the total number of patients will depend on the dose level at which the RP2D is defined. Patients who meet the eligibility criteria during Screening will enter the treatment period. ZB131 will be given via IV every week. Patients will be treated until disease progression or unacceptable toxicities occur. Once the RP2D has been established, the Dose Expansion stage will begin to enroll subjects by cohort. For each expansion cohort, subjects will be enrolled in two stages. The first stage includes an evaluation of 12 patients. If 1 or more of 12 patients have a CR or PR, then accrual will continue until a total of 37 patients with measurable disease have been enrolled. Additional patients may be added to ensure 37 subjects with measurable disease are available for evaluation
Intervention public domain (ClinicalTrials.gov)
Drug: ZB131. ZB131 will be administered once weekly by intravenous infusion with the weight at baseline used for mg/kg dose calculations.
Arm public domain (ClinicalTrials.gov)
Active Treatment: ZB131 (experimental): During the Dose Escalation Stage, patients will be treated with ZB131 at increasing dose levels, beginning with a starting dose level (DL0) of 3 mg/kg once weekly, up to a maximum dose level (DL3) of 15 mg/kg once weekly.
Primary outcome public domain (ClinicalTrials.gov)
Maximum plasma concentration (Cmax). Determine maximum plasma concentration (Cmax) Time frame: 1 month.
Eligibility public domain (ClinicalTrials.gov)
Inclusion Criteria: 1. Male or female ≥18 years of age at the time of signing informed consent. 2. Diagnosis of histologically or cytologically confirmed advanced solid tumors 1. Dose Escalation Stage: patients with solid tumors (excluding melanoma and hepatocellular CR) who have failed all available therapies or are not eligible for standard of care (SOC). 2. Dose Expansion Stage: i. Cohort A: Advanced or Metastatic Pancreatic Cancer (pancreatic ductal; adenocarcinoma) who have failed or are not eligible for SOC; ii. Cohort B: Advanced or Metastatic Ovarian Cancer of the serous type (ovarian serous adenocarcinoma; ovarian serous cystadenocarcinoma) who have failed or are not eligible for SOC; iii. Cohort C: Advanced or Metastatic Biliary Cancer (intrahepatic, extrahepatic, gallbladder) who have failed or are not eligible for SOC. 3. Eastern Cooperative Oncology Group (ECOG) status of 0-1. 4. Measurable disease per RECIST as assessed by local site investigator/radiologists; lesions situated in previous irradiated areas are considered measurable if progression has been demonstrated in such lesions. 5. Patients must have a tumor lesion that can be safely biopsied and agree to provide a fresh or archival tissue sample prior to treatment initiation and agree to an on-treatment biopsy. The on-treatment biopsy may be waived for patients in the Dose Escalation Stage if a biopsy sample is not possible. An archival sample must be ≤6 months old. 6. Locally advanced, recurrent, or metastatic neoplastic disease that has failed to respond to standard therapy, is not curable by currently available local therapies, or for whom no appropriate therapies are available (based on the judgement of the Investigator. 7. Life expectancy of ≥3 months in the judgement of the Investigator 8. Adequate hematologic function based on the following: a. Absolute neutrophil count ≥1.5 x 109/L b. Platelet count ≥100 x 109/L c. Hemoglobin ≥9.0 g/dL 9. Adequate coagulation parameters based on the following: a. Prothrombin Time-International Normalized Ratio/partial thromboplastin time (PT-INR/PTT) \< ) \<1.5 x ULN, unless coumarin derivatives are used; and b. Partial thromboplastin time (PTT) or activated partial thromboplastin time (APTT) \<1.25 x ULN (therapeutic anticoagulation. Note: Anti-coagulation therapy is allowed, if this treatment canpermitted but should be able to be interrupted for a biopsy as judgedif deemed necessary by the Investigator).. The coagulation parameters for …
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 35 participants (actual).